Therapeutic options in advanced cutaneous T cell lymphomas: a role for interferon alfa-2a (Roferon-A).

@article{Bunn1985TherapeuticOI,
  title={Therapeutic options in advanced cutaneous T cell lymphomas: a role for interferon alfa-2a (Roferon-A).},
  author={Paul A. Bunn and Kenneth A. Foon},
  journal={Seminars in oncology},
  year={1985},
  volume={12 4 Suppl 5},
  pages={18-24}
}
Interferon alfa-2a (Roferon-A) was given to 20 patients with advanced cutaneous T cell lymphomas, all of whom were heavily pretreated. Objective responses were seen in nine of the 20 patients, including seven partial and two complete responses. The median response duration was 5.5 months, with three of the responses lasting 2 or more years. Toxicity was… CONTINUE READING